Terns Pharmaceuticals Inc (TERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.77 Million) by net assets ($284.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TERN net asset quality score to measure how much of total assets are equity-financed.
Terns Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TERN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Terns Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Plaspac Public Company Limited
BK:TPAC
|
0.071x |
|
Peninsula Energy Ltd
AU:PEN
|
-0.085x |
|
Veracruz Properties SOCIMI SA
MC:YVCP
|
0.025x |
|
NIP Group Inc. American Depositary Shares
NASDAQ:NIPG
|
-0.004x |
|
Solborn Inc
KQ:035610
|
-0.027x |
|
Talga Group Ltd
F:TGX
|
-0.234x |
|
AXON PARTNERS GRP EO -10
F:XE1
|
N/A |
|
MEDIPOST Co. Ltd
KQ:078160
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Terns Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see TERN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $345.87 Million | $-70.02 Million | -0.202x | +23.29% |
| 2023-12-31 | $255.37 Million | $-67.39 Million | -0.264x | -48.82% |
| 2022-12-31 | $276.94 Million | $-49.11 Million | -0.177x | +32.04% |
| 2021-12-31 | $160.30 Million | $-41.83 Million | -0.261x | +39.96% |
| 2020-12-31 | $68.59 Million | $-29.81 Million | -0.435x | +87.97% |
| 2019-12-31 | $18.32 Million | $-66.22 Million | -3.614x | -1344.50% |
| 2018-12-31 | $72.23 Million | $-18.07 Million | -0.250x | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more